BACKGROUND The frequency of twin births has increased dramatically since the 1970s in nearly all developed countries. This upsurge poses a public health challenge because multiple pregnancies are ...
Percheron Therapeutics ( ($AU:PER) ) has issued an update. Percheron Therapeutics has announced the final results of its Phase I clinical trial ...
Percheron Therapeutics ( ($AU:PER) ) has issued an announcement. Percheron Therapeutics has made significant progress in the development of its ...
SAN DIEGO & HOUSTON & SINGAPORE--(BUSINESS WIRE)--Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic ...
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in ...
SAN FRANCISCO and SINGAPORE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat ...
HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback